1. ¹Sexual Health Fertility and Microsurgery, New York University School of Medicine, New York, NY, USA
2. ²Northeast Indiana Urology, PC, Fort Wayne, IN, USA
3. ³Urology Research Options, Aurora, CO, USA
4. ⁴Hudson Valley Urology, PC, Poughkeepsie, NY, USA
5. ⁵Pfizer Inc, New York, NY, USA

Correspondence: Dr AR McCullough, Sexual Health Fertility and Microsurgery, New York University School of Medicine, 150 East 32 Street, 2nd floor, New York, NY 10016, USA. E-mail: Andy.mccullough@nyumc.org

Received 18 February 2008; Revised 3 April 2008; Accepted 12 April 2008; Published online 5 June 2008.

Abstract

In two randomized, double-blind, placebo-controlled trials of 100 mg sildenafil citrate, men (N=601) with mild to moderate erectile dysfunction (ED) attempted intercourse 8 h (range, 7–9 h) postdose. The baseline to end-of-treatment improvement in the sildenafil groups vs placebo was greater (P<0.001) for the per-patient proportion (PPP) of 'yes' responses to the Sexual Encounter Profile question 3 (SEP3: successful intercourse (primary outcome)) (odds ratio (OR)=3.2 (trial 1), 7.6 (trial 2) and 5.6 (pooled data)); PPP of erection hardness score 4 (EHS 4, completely hard and fully rigid) (OR=6.2 (trial 1) and 10.9 (trial 2)); scores on the International Index of Erectile Function; and other EHS and SEP outcomes. Two to three times as many men were satisfied with sildenafil vs placebo treatment (Erectile Dysfunction Inventory of Treatment Satisfaction Index >50). Thus, responsiveness to 100 mg sildenafil may persist for 8 h postdose in men with mild to moderate ED.